Gang Zeng

Company: T-Cure Bioscience

Job title: President & Chief Executive Officer

Seminars:

All-Natural & High-Affinity TCR Enable CD8-Independent Func 4:00 pm

Discovery and validation of 806TCR using proprietary iSORT platform Empower CD4 T helper cells by transducing 806TCR CD8-independence makes 806TCR an excellent candidate for allogeneic and “off the shelf” modalitiesRead more

day: Conference Day Two

Panel: Comparing the Characteristics of TCR-T Cell Therapies & TCR Bispecifics (& More!) to Reaffirm their Unique Benefits 2:00 pm

Comparing relative affinities, potencies and safety considerations of T-cell therapies and bispecifics Assessing indications and patients where each TCR modality could be best suited to treat What other modalities can TCR therapies venture into in the future?Read more

day: Conference Day One